GeneDx Holdings Corp.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Katherine A. Stueland
- Full Time Employees
- 1,000
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- North Tower Stamford CT United States of America 06902
- IPO Date
- Nov 4, 2020
- CIK
- 0001818331
- Website
- genedx.com
- Similar Companies
- Business
- GeneDx Holdings Corp. operates as a genetic testing and genomic information company specializing in clinical genetic testing services and genomic diagnostics. It offers a comprehensive range of products and services including hereditary disease testing, rare and ultra-rare disease diagnostics, prenatal genetic testing, oncology-related genetic analysis, carrier screening, pharmacogenomics, and whole exome and genome sequencing assays. The company addresses clinical needs through specialized genetic tests, interpretation services, and advanced genomic data analysis primarily for healthcare providers, researchers, and pharmaceutical companies. Headquartered in Gaithersburg, Maryland, and founded in 2000, GeneDx serves a broad geographic market including the United States and international locations. Recent major company developments include strategic expansions in partnerships and service offerings to enhance precision medicine capabilities, with a focus on expanding its testing panels and integrating advanced bioinformatics tools. GeneDx has made significant strides in developing new genetic tests tailored for rare diseases and oncology, reflecting a strategic emphasis on personalized medicine and broader clinical application. These advancements are alongside ongoing investments in research and development to support novel diagnostic solutions. GeneDx is positioned within the molecular diagnostics and genomics industry, targeting clinicians, hospitals, research institutions, and biopharmaceutical firms. It is part of a growing sector driven by advances in genetic sequencing technologies and the increasing demand for personalized healthcare solutions. This detailed profile encapsulates GeneDx’s core business activities, product portfolio, recent strategic initiatives, industry context, and market focus, reflecting its role as a leading provider of genomic testing services.
GeneDx Holdings (WGS) 49% Drop Triggers Investor Scrutiny Over Disconnect From Prior Growth Narrative- HBSS
GeneDx Holdings (WGS) 49% Drop Triggers Investor Scrutiny Over Disconnect From Prior Growth Narrative – Hagens Berman
GeneDx Holdings (WGS) 49% Drop Triggers Investor Scrutiny Over Disconnect From Prior Growth Narrative – Hagens Berman
GeneDx to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS
Is GeneDx Stock a Buys After a Company Director Purchased Over 350,000 Shares?
Barrack, Rodos & Bacine Investigates GeneDx Holdings Corp. (NASDAQ: WGS) For Possible Securities Fraud
Barrack, Rodos & Bacine Investigates GeneDx Holdings Corp. (NASDAQ: WGS) For Possible Securities Fraud
GeneDx Holdings Corp. (WGS) Securities Fraud Investigation - Levi & Korsinsky
Bragar Eagel & Squire, P.C. is Investigating GeneDx Holdings Corp. (NASDAQ:WGS) on Behalf of GeneDx Stockholders and Encourages Investors with Losses to Contact the Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS
WGS SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
WGS SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Fraud Investigation Opened: Levi & Korsinsky Investigates GeneDx Holdings Corp. (WGS) on Behalf of Shareholders
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS
Levi & Korsinsky Announces Investigation of Securities Claims Against GeneDx Holdings Corp. (WGS)
GeneDx: Disappointing Q1 Creates Another Turnaround Opportunity
WGS SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
WGS Investor Alert: Levi & Korsinsky Investigates GeneDx Holdings Corp. (WGS) for Potential Securities Fraud
GeneDx: The 50% Crash Creates A Compelling Entry